Supplementary Figure S7 from Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study

Puntos clave

• Tumor mutational burden (TMB) distinguishes responders from non-responders to ipilimumab and nivolumab.
• In ipilimumab-high cohorts, TMB was observed to vary significantly between responders and non-responders.
• Observational analysis showed distinct TMB patterns for patients in both ipilimumab-high and ipilimumab-low cohorts.
• These findings highlight the potential role of TMB in predicting treatment outcomes for urothelial cancer.